Sarah C. Sasson

Sydney, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.

Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission.

Journal: Critical care medicine

Published: May 26, 2026

Immunocompromised patients with viral severe acute respiratory infection in intensive care: an Australia wide, retrospective, observational study.

Immunocompromised patients with viral severe acute respiratory infection in intensive care: an Australia wide, retrospective, observational study.

Journal: Critical care (London, England)

Published: May 11, 2026

Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial.

Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial.

Journal: BMJ open

Published: April 24, 2026

Concurrent renal amyloid light chain amyloidosis, light chain crystalline podocytopathy and light chain proximal tubulopathy: a case report.

Concurrent renal amyloid light chain amyloidosis, light chain crystalline podocytopathy and light chain proximal tubulopathy: a case report.

Journal: Pathology

Published: December 08, 2025

Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.

Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.

Journal: Frontiers in immunology

Published: December 05, 2025

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Journal: Internal medicine journal

Published: November 01, 2025

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm.

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm.

Journal: Internal medicine journal

Published: August 08, 2025

HPV status shapes T-cell immunoprofiles in oesophageal adenocarcinoma: high regulatory T cell infiltration predicts poor prognosis.

HPV status shapes T-cell immunoprofiles in oesophageal adenocarcinoma: high regulatory T cell infiltration predicts poor prognosis.

Journal: Journal of translational medicine

Published: June 02, 2025

A prediction model for 'ICU mortality or prolonged ICU stay' in critically unwell patients with acute pancreatitis: insights from a 2003-2020 cohort analysis using the ANZICS-CORE database.

A prediction model for 'ICU mortality or prolonged ICU stay' in critically unwell patients with acute pancreatitis: insights from a 2003-2020 cohort analysis using the ANZICS-CORE database.

Journal: Critical care (London, England)

Published: June 02, 2025

Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans.

Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans.

Journal: The Journal of clinical investigation

Published: February 27, 2025

Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia.

Expanded CD16+CD56+Granzyme B+ NK like CD8+ T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia.

Journal: Scientific reports

Published: February 10, 2025

Response to Letter to the Editor from Hao and Xue: "Checkpoint Inhibitor-associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy".

Response to Letter to the Editor from Hao and Xue: "Checkpoint Inhibitor-associated Autoimmune Diabetes Mellitus Is Characterized by C-Peptide Loss and Pancreatic Atrophy".

Journal: The Journal of clinical endocrinology and metabolism

Published: July 03, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026